<乌鸦传媒>NASH Drug Candidate Comes With 'Serious Risks,' Says FDA Staff Agency reviewers signal little support for first potential nonalcoholic steatohepatitis drug May 17, 2023
<乌鸦传媒>Statins Linked to Slower Liver Disease Progression Risk 40% lower with use among those with preexisting liver disease, study found May 04, 2023
<乌鸦传媒>Bariatric-Metabolic Surgery More Effective Than Lifestyle Change for NASH Roux-en-Y bypass or sleeve gastrectomy resolved NASH without exacerbating liver fibrosis Apr 26, 2023
<乌鸦传媒>Transplant Chief Was an Organ Recipient Herself Years ago, she had a liver transplant. Now she leads Hopkins' pediatric liver transplant program Apr 19, 2023
<乌鸦传媒>NKF Roundup: Latest Data on Tolvaptan, Terlipressin, and Lumasiran More research from the National Kidney Foundation Spring Clinical Meeting Apr 17, 2023
<乌鸦传媒>Adjuvant Combo May Change Practice in High-Risk Liver Cancer Atezolizumab-bevacizumab reduced the risk of recurrence by about 30% Apr 17, 2023
<乌鸦传媒>Another Measure of Terlipressin Success in Hepatorenal Syndrome Goal of 30% reduction in serum creatinine in the absence of full response or HRS reversal Apr 13, 2023
<乌鸦传媒>Smaller Liver Transplant Candidates Wait Longer, Less Likely to Receive Organ Disparity mostly affects women, but allocating more livers from smaller donors may help Mar 29, 2023
<乌鸦传媒>FDA Mandate on Acetaminophen-Opioid Combinations Appeared Effective Hospitalizations for liver toxicity declined after FDA limited acetaminophen dose Mar 07, 2023
<乌鸦传媒>Avoiding Just This Dietary Trigger Helps Resolve Eosinophilic Esophagitis Easier alternative to six-food elimination diet shown effective Mar 01, 2023
<乌鸦传媒>'More Is Not Better' in Two First-Line Trials for Biliary Tract Cancer No survival benefit with three-drug chemo regimen or clear PFS gain with anti-PD-L1/bevacizumab Jan 22, 2023
<乌鸦传媒>Epstein-Barr Virus Tracking After Liver Transplant May Cut Rare Complication Observational study provides suggestive evidence Jan 17, 2023
<乌鸦传媒>Direct-Acting Antivirals Linked to Improved Outcomes in Chronic Hepatitis C All-cause mortality rate significantly lower in treated versus untreated group Dec 13, 2022
<乌鸦传媒>Abstinence Tied to Lower Mortality in Alcoholic Cirrhosis With Portal Hypertension Benefit observed even in patients with high-risk portal hypertension Dec 08, 2022
<乌鸦传媒>Robotic Surgery Proves Its Mettle for Liver Cancer Fewer cases of liver failure, similar survival versus open liver resection in matched analysis Nov 23, 2022
<乌鸦传媒>Will Fresh Look at Obeticholic Acid Data in NASH Sway FDA? Latest REGENERATE analysis comes on heels of REVERSE flop Nov 11, 2022
<乌鸦传媒>Steroids and G-CSF Boost 90-Day Survival in Severe Alcoholic Hepatitis Plus: Normothermic machine perfusion for liver transplants and Noom Weight for NASH Nov 11, 2022
<乌鸦传媒>Novel Hepatitis B Drug Hints at Long-Term 'Functional Cure' for Some in Early Trial With 10% efficacy at 6 months post-treatment, a finite HBV treatment may be on the horizon Nov 10, 2022
<乌鸦传媒>Efruxifermin Led to NASH Resolution, Fibrosis Improvement in Mid-Stage Trial Both 50- and 28-mg doses improved fibrosis vs placebo, without worsening of NASH Nov 10, 2022
<乌鸦传媒>Maralixibat Takes Out the Itch of Rare Liver Disease Ileal bile acid transporter inhibitor could become second drug for PFIC Nov 09, 2022
<乌鸦传媒>Odevixibat Shows 'Encouraging Results' for Kids With Alagille Syndrome Significant improvements in itching, bile acid levels for rare, life-threatening liver disorder Nov 09, 2022
<乌鸦传媒>Acamprosate Appears Safe for People With AUD and Liver Disease Phase II data suggest drug is well-tolerated and can reduce cravings in this group of patients Nov 09, 2022
<乌鸦传媒>BP Control Beneficial for Liver Transplant Recipients Patients who kept their blood pressure under 140/90 mm Hg had better kidney function at 1 year Nov 07, 2022
<乌鸦传媒>Earlier Terlipressin May Be Better for HRS-AKI in Acute-on-Chronic Liver Failure More acute kidney injury reversals at 7 days and lower mortality with initiation at 12 hours Nov 07, 2022
<乌鸦传媒>Pandemic's Impact on Liver Disease in the Spotlight at Liver Meeting A roundup of news from the AASLD annual meeting Nov 04, 2022
<乌鸦传媒>New HRS Drug Cuts Need for Renal Replacement Tx After Liver Transplant Follow-up data from CONFIRM trial show terlipressin benefit in key subgroup Oct 25, 2022
<乌鸦传媒>New Standard-of-Care Therapy for Advanced Liver Cancer Stereotactic body radiotherapy plus sorafenib improves survival versus targeted drug alone Oct 24, 2022
<乌鸦传媒>FDA Approves New CTLA-4 Inhibitor for Cancer Treatment Tremelimumab (Imjudo), in combination with durvalumab, lands approval in advanced liver cancer Oct 24, 2022
<乌鸦传媒>Bariatric Surgery in NAFLD Tied to Lower Heart Disease Risk In a large cohort, surgery associated with 49% lower risk of CVD versus nonsurgical care Oct 07, 2022
<乌鸦传媒>Noninvasive Gastric Mapping; Best Foods for the Gut? Lab Score for Crohn's News and commentary from the world of gastroenterology and hepatology Sep 22, 2022
<乌鸦传媒>Obeticholic Acid Tied to Better Outcomes in Primary Biliary Cholangitis Study comparing randomized trial with two external cohorts showed fewer deaths, transplants Sep 22, 2022
<乌鸦传媒>FDA Finally OKs First Drug for Hepatorenal Syndrome Pivotal trial data showed terlipressin nearly doubled reversal of the condition Sep 15, 2022
<乌鸦传媒>Ryan Reynolds' Colonoscopy; NASH Drug Passes Phase II Test; New Drug Target in IBD? News and commentary from the world of gastroenterology and hepatology Sep 14, 2022
<乌鸦传媒>More GI Docs, Fewer Alcoholic Liver Disease Deaths Study suggests access might account for 40% of alcohol-associated liver disease deaths nationally Aug 08, 2022
<乌鸦传媒>Adding TACE to Lenvatinib Boosts Survival in Advanced Liver Cancer In China-based trial, overall survival in first-line improved by 6 months versus lenvatinib alone Aug 04, 2022
<乌鸦传媒>Rare Mutations Linked to Protection Against Liver Disease Carriers of CIDEB variants were at lower risk for liver disease of any cause, study shows Jul 27, 2022
<乌鸦传媒>Novel Antifibrotic Improved Fibrosis in Chronic Hepatitis B Phase II trial from China suggests benefit of add-on therapy Jul 15, 2022
<乌鸦传媒>Unexplained Acute Hepatitis in Children: More Evidence for Adenovirus 41 Two studies point to a suspiciously high prevalence Jul 13, 2022
<乌鸦传媒>Odevixibat Scratches the Itch of Kids' Rare Liver Disease Phase III trial showed reduced pruritus in progressive familial intrahepatic cholestasis Jul 08, 2022
<乌鸦传媒>Hep C Cure Aside, Some Patients Still Benefit From Liver Cancer Screening Hepatocellular carcinoma risk persisted after direct-acting antivirals Jun 30, 2022
